Companies are fighting for strong relationships with key opinion leaders—and Genentech is winning, hands down.
Genentech had previously been number one by a very wide margin. This year, that margin started to narrow. Novartis is now a much closer second
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva